Stock Track | Cardinal Health Soars 9.44% Pre-market on Strong Q1 Results and Raised Outlook

Stock Track

Oct 30

Cardinal Health (NYSE:CAH) shares surged 9.44% in pre-market trading on Thursday following the release of its impressive first-quarter fiscal year 2026 results and an upgraded full-year outlook. The healthcare services and products company significantly outperformed analyst expectations, demonstrating robust growth across its business segments.

The company reported first-quarter revenue of $64 billion, a substantial 22% increase from the previous year and well above the consensus estimate of $59.347 billion. Adjusted earnings per share (EPS) came in at $2.55, surpassing the analyst expectations of $2.19 and marking a 36% year-over-year growth. The strong performance was primarily driven by the Pharmaceutical and Specialty Solutions segment, which saw a 23% revenue increase and a 26% profit growth.

In light of the strong results, Cardinal Health raised its fiscal year 2026 guidance. The company now expects non-GAAP EPS in the range of $9.65 to $9.85, up from previous estimates and surpassing the FactSet consensus of $9.44. Additionally, Cardinal Health increased its fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billion. The company also announced the initiation of a $375 million accelerated share repurchase program in Q1, further boosting investor confidence. With the anticipated completion of the Solaris Health acquisition in early November, Cardinal Health appears well-positioned for continued growth and expansion in the healthcare sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1162459212"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162459212\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162459212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162459212","market":"sg","top_or_hot":-1,"title":"Stock Track | Cardinal Health Soars 9.44% Pre-market on Strong Q1 Results and Raised Outlook","media":"Stock Track","content":"<p>Cardinal Health (NYSE:CAH) shares surged 9.44% in pre-market trading on Thursday following the release of its impressive first-quarter fiscal year 2026 results and an upgraded full-year outlook. The healthcare services and products company significantly outperformed analyst expectations, demonstrating robust growth across its business segments.</p>\n\n<p>The company reported first-quarter revenue of $64 billion, a substantial 22% increase from the previous year and well above the consensus estimate of $59.347 billion. Adjusted earnings per share (EPS) came in at $2.55, surpassing the analyst expectations of $2.19 and marking a 36% year-over-year growth. The strong performance was primarily driven by the Pharmaceutical and Specialty Solutions segment, which saw a 23% revenue increase and a 26% profit growth.</p>\n\n<p>In light of the strong results, Cardinal Health raised its fiscal year 2026 guidance. The company now expects non-GAAP EPS in the range of $9.65 to $9.85, up from previous estimates and surpassing the FactSet consensus of $9.44. Additionally, Cardinal Health increased its fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billion. The company also announced the initiation of a $375 million accelerated share repurchase program in Q1, further boosting investor confidence. With the anticipated completion of the Solaris Health acquisition in early November, Cardinal Health appears well-positioned for continued growth and expansion in the healthcare sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cardinal Health Soars 9.44% Pre-market on Strong Q1 Results and Raised Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cardinal Health Soars 9.44% Pre-market on Strong Q1 Results and Raised Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-30 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cardinal Health (NYSE:CAH) shares surged 9.44% in pre-market trading on Thursday following the release of its impressive first-quarter fiscal year 2026 results and an upgraded full-year outlook. The healthcare services and products company significantly outperformed analyst expectations, demonstrating robust growth across its business segments.</p>\n\n<p>The company reported first-quarter revenue of $64 billion, a substantial 22% increase from the previous year and well above the consensus estimate of $59.347 billion. Adjusted earnings per share (EPS) came in at $2.55, surpassing the analyst expectations of $2.19 and marking a 36% year-over-year growth. The strong performance was primarily driven by the Pharmaceutical and Specialty Solutions segment, which saw a 23% revenue increase and a 26% profit growth.</p>\n\n<p>In light of the strong results, Cardinal Health raised its fiscal year 2026 guidance. The company now expects non-GAAP EPS in the range of $9.65 to $9.85, up from previous estimates and surpassing the FactSet consensus of $9.44. Additionally, Cardinal Health increased its fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billion. The company also announced the initiation of a $375 million accelerated share repurchase program in Q1, further boosting investor confidence. With the anticipated completion of the Solaris Health acquisition in early November, Cardinal Health appears well-positioned for continued growth and expansion in the healthcare sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAH","symbol_name":"卡地纳健康","start_time":0,"source_url":"","article_id":"1162459212","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162459212","pubTimestamp":1761822047,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Cardinal Health (NYSE:CAH) shares surged 9.44% in pre-market trading on Thursday following the release of its impressive first-quarter fiscal year 2026 results and an upgraded full-year outlook. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAH":"卡地纳健康"},"translate_title":"个股追踪|康德乐Q1业绩强劲，展望上调，盘前大涨9.44%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAH":1},"content_text":"Cardinal Health (NYSE:CAH) shares surged 9.44% in pre-market trading on Thursday following the release of its impressive first-quarter fiscal year 2026 results and an upgraded full-year outlook. The healthcare services and products company significantly outperformed analyst expectations, demonstrating robust growth across its business segments.\nThe company reported first-quarter revenue of $64 billion, a substantial 22% increase from the previous year and well above the consensus estimate of $59.347 billion. Adjusted earnings per share (EPS) came in at $2.55, surpassing the analyst expectations of $2.19 and marking a 36% year-over-year growth. The strong performance was primarily driven by the Pharmaceutical and Specialty Solutions segment, which saw a 23% revenue increase and a 26% profit growth.\nIn light of the strong results, Cardinal Health raised its fiscal year 2026 guidance. The company now expects non-GAAP EPS in the range of $9.65 to $9.85, up from previous estimates and surpassing the FactSet consensus of $9.44. Additionally, Cardinal Health increased its fiscal year 2026 non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billion. The company also announced the initiation of a $375 million accelerated share repurchase program in Q1, further boosting investor confidence. With the anticipated completion of the Solaris Health acquisition in early November, Cardinal Health appears well-positioned for continued growth and expansion in the healthcare sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}